Project CBD Newsletter: FDA CBD Gummy Recall, Magic Mushroom Edibles Contain No Psilocybin, CBD for Obesity, Acupuncture and the Endocannabinoid System, and Psychedelic-Associated Depersonalization Disorder
This week’s newsletter covers a major CBD product recall, surprising findings about “magic mushroom” edibles, promising preclinical research on CBD for metabolic health, acupuncture’s link to the endocannabinoid system, and a review of psychedelic-associated depersonalization disorder.
Noteworthy Read
Extract Labs Issues National CBD Gummy Recall (Prevention)
The brand Extract Labs has issued a national recall of around 60,000 CBD gummy products due to potential issues with labeling, potency, or contamination, urging consumers to check lot numbers and avoid consumption.
View more in CBD
More Noteworthy Reading
Some “Magic Mushroom” Edibles Have Zero Psilocybin (Gizmodo)
Testing of several commercial “magic mushroom” edibles revealed that many contain no psilocybin at all; instead, they list generic plant material with nonpsychedelic substances that may cause unknown psychoactive effects.
View more in Psychedelics
Research Round-Up
CBD Shows Promise for Obesity and Metabolic Syndrome (MedicalNet.news)
Preclinical models suggest that cannabidiol (CBD) may reduce overeating, improve glucose and lipid metabolism, and dampen inflammation, though large, well-controlled human trials are still needed.
View more in CBD
Preclinical Research: Acupuncture Relieves Fibromyalgia Pain via Endocannabinoid System (Biomedicines / PubMed)
In animal models, acupuncture appears to reduce fibromyalgia-like pain and improve associated symptoms by modulating endocannabinoid signaling pathways, suggesting a possible mechanistic link.
View more in Endocannabinoid System
Psychedelic-Associated Depersonalization Disorder (PubMed)
This paper reviews cases and mechanisms of depersonalization disorder linked to psychedelic use, examining how altered neural circuits, dissociative states, and receptor dynamics may contribute to persistent identity disruption in some users.
View more in Psychedelics
A heartfelt thank you to all of the CBD brands whose generous support makes it possible for Project CBD to bring you the latest in plant medicine research and journalism each week — we couldn’t do it without you.
